The increase in price target from $32 to $45 by Morgan Stanley indicates a more optimistic view on PTC Therapeutics' future performance. Maintaining an Equal-Weight rating suggests that while the stock is expected to perform well, it may not outperform the market significantly. This news is likely to have a positive short-term impact on the stock price as it reflects increased confidence from a major financial institution.